{"id":"W2761129333","doi":"10.1007/s11060-017-2624-4","title":"Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02","year":2017,"lang":"en","type":"article","venue":"Journal of Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; Public Health Ontario","funders":"National Cancer Institute; National Institutes of Health","keywords":"Sorafenib; Medicine; Internal medicine; Oncology; Toxicity; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003449381,0.0001524708,0.000798561,0.0002027467,0.0001538614,0.00002294477,0.0001548219,0.00008540053,0.00001991212],"category_scores_gemma":[0.0006325557,0.00009926855,0.0001635362,0.00004351946,0.00009948587,0.0001009716,0.00007003349,0.0002238676,0.00000178061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008729216,"about_ca_system_score_gemma":0.0001595328,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005855141,"about_ca_topic_score_gemma":0.00004093328,"domain_scores_codex":[0.9986887,0.00009008768,0.0006209412,0.0001791653,0.0002245865,0.0001965433],"domain_scores_gemma":[0.9975705,0.0003820235,0.001199938,0.0002981438,0.0003384706,0.0002109466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02758004,0.09976969,0.03627968,0.000245122,0.001774869,0.009990913,0.003651569,0.0000145412,0.121017,0.0001159851,0.032328,0.6672326],"study_design_scores_gemma":[0.164419,0.5724291,0.04214203,0.0002210845,0.002709281,0.005268054,0.001564962,0.0002560168,0.02670166,0.0002336476,0.183795,0.000260243],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993558,0.0004178179,0.00001057705,0.00426326,0.0009070685,0.0006875657,0.000012578,0.000004948089,0.000138194],"genre_scores_gemma":[0.9990286,0.0002098477,0.0002674084,0.0001645844,0.0002721446,0.00002363057,8.839768e-7,0.0000183318,0.00001459924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6669723,"threshold_uncertainty_score":0.4048054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05229702977251907,"score_gpt":0.3962628312140511,"score_spread":0.3439658014415321,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}